Oncolytics Biotech, Inc. (NASDAQ:ONCY) Q4 2023 Earnings Conference Call March 7, 2024 4:30 PM ET Company Participants Jon Patton - Director, IR & Communications Matt Coffey - CEO Kirk Look - CFO Tom Heineman - CMO Allison Hagerman - VP, Product Development Conference Call Participants Soumit Roy - Jones Research John Newman - Canaccord Luis Santos - H.C. Wainwright Carvey Leung - Cantor Operator Good afternoon, and welcome to Oncolytics Biotech's Fourth Quarter and Full Year 2023 Conference Call. All partic ...

Oncolytics Biotech Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights ® Management hosting conference call and webcast today at 4:30 p.m. ET SAN DIEGO, CA and CALGARY, AB, March 7, 2024 -- Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced recent operational highlights and financial results for the fourth quarter and year ended December 31, 2023. All dollar amounts are expressed in Canadian c ...

Oncolytics Biotech Inc. (NASDAQ:ONCY) Q3 2023 Earnings Conference Call November 3, 2023 8:30 AM ET Company Participants Jon Patton - Director, IR Matt Coffey - President & CEO Thomas Heineman - Chief Medical Officer Andrew de Guttadauro - Global Head of Business Development, President, Oncolytics Biotech (U.S.) Inc. Kirk Look - CFO Conference Call Participants Louise Chen - Cantor John Newman - Canaccord Soumit Roy - JonesTrading Operator Good morning, and welcome to Oncolytics Biotech's Third Quarter 2023 ...

Condensed Interim Consolidated Financial Statements (unaudited) Oncolytics Biotech Inc. For the three and nine months ended September 30, 2023 ® ONCOLYTICS BIOTECH INC. CONDENSED INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (unaudited) (in thousands of Canadian dollars, except share amounts) | | | September 30, | | December 31, | | --- | --- | --- | --- | --- | | As at | | 2023 | | 2022 | | Assets | | | | | | Current assets | | | | | | Cash and cash equivalents (note 4) | $ | 39,981 | $ | 11,666 | ...

Oncolytics Biotech Inc. (NASDAQ:ONCY) Q2 2023 Earnings Conference Call August 14, 2023 8:30 AM ET Company Participants Jon Patton - Director-Investor Relations and Communications Matt Coffey - President and Chief Executive Officer Thomas Heineman - Chief Medical Officer Andrew de Guttadauro - Global Head of Business Development, President, Oncolytics Biotech (U.S.) Inc. Kirk Look - Chief Financial Officer Conference Call Participants Patrick Trucchio - H.C. Wainwright Soumit Roy - JonesTrading John Newman ...

2 ONCOLYTICS BIOTECH INC. Condensed Interim Consolidated Financial Statements (unaudited) Oncolytics Biotech Inc. For the three and six months ended June 30, 2023 ® ONCOLYTICS BIOTECH INC. CONDENSED INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (unaudited) (in thousands of Canadian dollars, except share amounts) | | | June 30, | | December 31, | | --- | --- | --- | --- | --- | | As at | | 2023 | | 2022 | | Assets | | | | | | Current assets | | | | | | Cash and cash equivalents (note 4) | $ | 17,520 ...

Oncolytics Biotech Inc. (NASDAQ:ONCY) Q1 2023 Earnings Conference Call May 5, 2023 8:30 AM ET Company Participants Jon Patton – Director-Investor Relations and Communications Matt Coffey – Chief Executive Officer Thomas Heineman – Chief Medical Officer Andrew de Guttadauro – Global Head of Business Development Kirk Look – Chief Financial Officer Conference Call Participants John Newman – Canaccord Louise Chen – Cantor Fitzgerald Patrick Trucchio – H.C. Wainwright Douglas Miehm – RBC Capital Markets Opera ...

Condensed Interim Consolidated Financial Statements (unaudited) Oncolytics Biotech Inc. For the three months ended March 31, 2023 ® ONCOLYTICS BIOTECH INC. CONDENSED INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (unaudited) (in thousands of Canadian dollars, except share amounts) | | | March 31, | | December 31, | | --- | --- | --- | --- | --- | | As at | | 2023 | | 2022 | | Assets | | | | | | Current assets | | | | | | Cash and cash equivalents (note 4) | $ | 15,872 | $ | 11,666 | | Marketable secu ...

Oncolytics Biotech Inc. (NASDAQ:ONCY) Q4 2022 Earnings Conference Call March 3, 2023 8:30 AM ET Company Participants Jon Patton - Director, Investor Relations and Communications Matt Coffey - Chief Executive Officer Thomas Heineman - Chief Medical Officer Andrew de Guttadauro - Global Head, Business Development Kirk Look - Chief Financial Officer Conference Call Participants John Newman - Canaccord Genuity Patrick Trucchio - H.C. Wainwright Operator Welcome to Oncolytics Biotech’s Fourth Quarter and Full Ye ...

o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For fiscal year ended December 31, 2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____ to ____ OR o SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE ...